Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Interim Measures for Implementation of the Amended Patent Law in the PRC

By Yingli Wang & Perkins Coie on May 28, 2021
Email this postTweet this postLike this postShare this post on LinkedIn

On May 25, 2021, the China National Intellectual Property Administration (CNIPA) issued the interim measures for processing of related examination businesses regarding the implementation of the amended patent law (the Measures).[1] Both the Measures and the amended patent law (the Law) will take effect on June 1, 2021.

The Measures allow applicants to submit applications or petitions for the following, which will be examined after the implementing regulations of the Law take effect:

  1. Design patent applications filed on or after June 1, 2021: design patent protection for partial design (the Law, Art. 2(4), the Measures, Art. 1); domestic priority claim (the Law, Art. 29(2), the Measures, Art. 3).
  2. Grace period of disclosure for patent applications filed on or after June 1, 2021: first disclosure for public interests in emergency of the state (the Law, Art. 24(1), the Measures, Art. 1).
  3. Patent term compensation for invention patents issued on or after June 1, 2021, due to the unreasonable delays caused by the CNIPA during prosecution can be requested by the patentee within three months from the issuance of the patent (the Law, Art. 42(2), the Measures, Art. 5).
  4. Patent term compensation for invention patents “related to new drugs that receive marketing approval in China” for marketing approval can be requested by the patentee within three months from the approval on or after June 1, 2021 (the Law, Art. 42(3), the Measures, Art. 6).

[1] The CNIPA issued the notice on the Measures on May 25, 2021. See https://www.cnipa.gov.cn/art/2021/5/25/art_564_159634.html.

Photo of Yingli Wang Yingli Wang

Dr. Yingli Wang is partner in the firm’s Intellectual Property practice, with a primary focus on biotechnology, pharmaceutical, and polymer/material industry. Yingli leads the patent group in the firm’s Shanghai office.

Read more about Yingli WangEmail
  • Posted in:
    Intellectual Property
  • Blog:
    China IP Legal Report
  • Organization:
    Perkins Coie LLP
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo